Role of CYP2C19 pharmacogenetic polymorphism on response of esomeprazole in the treatment of GERD

被引：0
|
作者：
Halimi, Shafarul
Abu Hassan, Muhammad Radzi
Ismail, Rusli
Kiew, Kuang Kiat
Zainuddin, Zalwani
Mustapha, Mohd Nazri
Mokhtar, Suraya
机构：
[1] Univ Sains Malaysia, George Town, Malaysia
[2] Hosp Univ Sains Malaysia, George Town, Malaysia
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2013年 / 28卷
关键词：
pharmacogenetics; polymorphism; GERD;
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：67 / 68
页数：2
相关论文
共 50 条
  • [31] CYP2C19 Genetic Polymorphism in Saudi Arabians
    Al-Jenoobi, Fahad I.
    Alkharfy, Khalid M.
    Alghamdi, Amal M.
    Bagulb, Khawla M.
    Al-Mohizea, Abdullah M.
    Al-Muhsen, Saleh
    Halwani, Rabih
    Parvez, Mohammad Khalid
    Al-Dosari, Mohammed S.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2013, 112 (01) : 50 - 54
  • [32] Genetic Polymorphism of CYP2C19 in Pakistani Population
    Riaz, Sana
    Din, Sadia Muhammad
    Tareen, Muhammad Usman
    Tariq, Fizza
    Latif, Yusra
    Siddiqi, Saima
    Sultan, Aneesa
    Mansoor, Atika
    IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH, 2019, 18 (02): : 1097 - 1102
  • [33] CYP2C19 polymorphism and risk for essential tremor
    Alonso-Navarro, Hortensia
    Martinez, Carmen
    Garcia-Martin, Elena
    Benito-Leon, Julian
    Garcia-Ferrer, Isabel
    Vazquez-Torres, Pilar
    Puertas, Inmaculade
    Lopez-Alburquerque, Tomas
    Agundez, Jose A. G.
    Jimenez-Jimenez, Felix Javier
    EUROPEAN NEUROLOGY, 2006, 56 (02) : 119 - 123
  • [34] Frequency of CYP2C19 Polymorphism in Ischemic Patients
    Shawky, A.
    PUBLIC HEALTH GENOMICS, 2018, 21 : 15 - 15
  • [35] INDIVIDUAL DIFFERENCES OF CYP2C19 mRNA EXPRESSION AND CYP2C19 GENETIC POLYMORPHISM IN THE SMALL INTESTINE OF JAPANESE
    Hayashi, Mikihilo
    Kinoshita, Yoichi
    Takenoshita, Sachiko
    Kurnai, Toshio
    Matsumoto, Naoki
    Kobayashi, Shinichi
    JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (09): : 1106 - 1106
  • [36] CYP2C19 polymorphism affects the treatment effects for reflux esophagitis with lansoprazole
    Kawamura, M
    Ohara, S
    Sekine, H
    Koike, T
    Abe, Y
    Shimosegawa, T
    Yoshida, M
    Kitagawa, Y
    GASTROENTEROLOGY, 2002, 122 (04) : A195 - A195
  • [37] The CYP2C19 Intron 2 Branch Point SNP is the Ancestral Polymorphism Contributing to the Poor Metabolizer Phenotype in Livers with CYP2C19☆35 and CYP2C19☆2 Alleles
    Chaudhry, Amarjit S.
    Prasad, Bhagwat
    Shirasaka, Yoshiyuki
    Fohner, Alison
    Finkelstein, David
    Fan, Yiping
    Wang, Shuoguo
    Wu, Gang
    Aklillu, Eleni
    Sim, Sarah C.
    Thummel, Kenneth E.
    Schuetz, Erin G.
    DRUG METABOLISM AND DISPOSITION, 2015, 43 (08) : 1226 - 1235
  • [38] The CYP2C19*2 and CYP2C19*17 Polymorphisms Influence Responses to Clozapine for the Treatment of Schizophrenia
    Rodrigues-Silva, Christielly
    Semedo, Agostinho Tavares
    da Silva Neri, Hiasmin Franciely
    Vianello, Rosana Pereira
    Galaviz-Hernandez, Carlos
    Sosa-Macias, Martha
    de Brito, Rodrigo Bernini
    Ghedini, Paulo Cesar
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2020, 16 : 427 - 432
  • [39] CYP2C19 variation and citalopram response
    Mrazek, David A.
    Biernacka, Joanna M.
    O'Kane, Dennis J.
    Black, John L.
    Cunningham, Julie M.
    Drews, Maureen S.
    Snyder, Karen A.
    Stevens, Susanna R.
    Rush, Augustus John
    Weinshilboum, Richard M.
    PHARMACOGENETICS AND GENOMICS, 2011, 21 (01): : 1 - 9
  • [40] The effect of CYP2C19 and CYP2C9 polymorphism on the pharmacodynamics of clopidogrel
    Jiang, Juanjuan
    Tian, Lei
    Han, Lulu
    Yan, Yan
    Huang, Yiling
    Liu, Hong
    Xie, Shuang
    Li, Yishi
    CARDIOLOGY, 2011, 120 : 30 - 31
12345